Trial Profile
A Phase I Pharmacologic Study of Oral Sapacitabine in Patients With Advanced Leukemias or Myelodysplastic Syndromes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs Sapacitabine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 30 Nov 2009 Results were published in the Journal of Clinical Oncology, according to a Cyclacel Pharmaceuticals media release.
- 27 Oct 2009 Actual end date (1 Jun 2009) added as reported by ClinicalTrials.gov.
- 27 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.